Нанотехнологии в медицине: состояние и перспективы

: . . . . : , of Health, USA) (National Institutes 10-12 m 10-9 m (pm) (nm) 10-7 m 10-6 m (μm) , (0,1-0,5nm) , , (1 -100 nm) (100 nm) (0,1-10 nm) 10-3 m 1m (mm) (0,1 -10 μm) (10 μm) (1 mm >) (100 μm) (1 μm) (10 μm) (1 sm) (( ,, ,, )) ,, ,, ,, , , , , « , » « , » Harisinghani MG et al., N EnglJ Med 348:2491–2499,2003. - Jaffer FA ,Weissleder R. JAMA293:855–862,2005. ( ) ( ) han WC et al , Curr Opin Biotechnol1 3:40–46,2002. 100 , Ginger DS et al , Angew Chem Int Ed Engl 43:30–45,2004 ( 100 ) Larson DR et al.. Science300:1434–1436,2003 quantum dots « »- 100- - , , , , , , , - (nanoshells) Halas N: Cancer nanotechNOVAscienceNOW, www.pbs.org/wgbh/nova/sciencenow/3209/03-canc-nf.html. Accessed March 2006. / / / VEGF -165 ,7 , 14 * * 300 200 200 100 100 - - 300 PBS β−Gal hVEGF PBS β−Gal ,7 , 14 * 40 hVEGF * 40 30 20 20 10 10 % 30 - - 30 VEGF PBS β−Gal hVEGF PBS β−Gal * hVEGF 20 n=8 10 VEGF n=12 n=11 VEGF * - p < 0.05 phVEGF165 8 Julian Baum/Science Photo Library . , nanotech-now.com – 7 nm REGULATORY LIGHT CHAIN ESSENTIAL LIGHT CHAIN II , - - – 4-5 – HeLa Belousov VV et al. Nature Methods. 2006 Apr;3(4):281-6 , ( , , ) , ( , , .) in vitro , : 1. 2. 3. • • • • • . . 1. Lukyanov KA, Chudakov DM, Fradkov AF, Labas YA, Matz MV, Lukyanov S. Discovery and properties of GFP-like proteins from nonbioluminescent anthozoa. Methods Biochem Anal. 2006; 47:121-38 2. Bulina ME, Lukyanov KA, Britanova OV, Onichtchouk D, Lukyanov S, Chudakov DM. Chromophore-assisted light inactivation (CALI) using the phototoxic fluorescent protein KillerRed. Nature Protocols. 2006;1: 947-953 3. Gurskaya NG, Verkhusha VV, Shcheglov AS, Staroverov DB, Chepurnykh TV, Fradkov AF, Lukyanov S, Lukyanov KA. Engineering of a monomeric green-tored photoactivatable fluorescent protein induced by blue light. Nature Biotechnology. 2006 Apr;24(4):461-5 4. Belousov VV, Fradkov AF, Lukyanov KA, Staroverov DB, Shakhbazov KS, Terskikh AV, Lukyanov S. Genetically encoded fluorescent indicator for intracellular hydrogen peroxide. Nature Methods. 2006 Apr;3(4):281-6 5. Bulina ME, Chudakov DM, Britanova OV, Yanushevich YuG, Staroverov DB, Chepurnykh TV, Merzlyak EM, Shkrob MA, Lukyanov S, Lukyanov KA. A genetically encoded photosensitizer. Nature Biotechnology. 2006; 24(1):95-9 6. Chudakov DM, Lukyanov S, Lukyanov KA. Fluorescent proteins as a toolkit for in vivo imaging. Trends Biotechnology. 2005 Dec;23(12):605-13 – , NO- ( , , , 2+) (HyPer) - "Nature Methods" "Society for Free Radicals Research" • , . • , . • – , , . Park SJ et al. , Science295:1503–506,2002. , - + Rosi NR ,Mirkin CA: Chem Rev105:1547–1562,2005 , - Hong JW wt al, Nat Biotechnol 22:435–439,2004. , C , % GFP+ 100 80 60 40 + GFP 20 Day 1 - 103 % GFP + 98% M1 - . , GFP 7 100 80 5 60 3 40 20 1 10 , 20 30 0 0 10 , 20 30 C 3 3 7 – ( , , , .) : in vitro in vivo, Dahan M et al., Science302:442–445,2003 . -Gal -Gal VEGF [VEGF], / 400 350 300 250 200 150 100 50 Control pVEGF vector ( % - ) * 70 % 30 * * 20 uPA VEGF ** 50 * 30 * -- p<0.05 * * p<0.01 10 10 uPA VEGF * 40 5 * 20 15 20 *** \ , mg/g 30 10 *** 4 3 / 2 10 1 - uPA VEGF * - p< 0.01 uPA VEGF - Neuwelt EA et al, Neuropathol Appl Neurobiol 30:456–471,2004.